Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Delcath Systems, focused on liver-directed treatments, announced its participation in two investor conferences. The first is the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:30 PM EDT, featuring a live webcast. The second event is the Oppenheimer Fall Healthcare Life Science & Med Tech Summit on September 23, 2020. Virtual one-on-one meetings with management can be scheduled. Delcath's investigational product, Melphalan Hydrochloride for Injection, targets liver cancer treatment and has not yet received FDA approval.

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences:

• H.C. Wainwright 22nd Annual Global Investment Conference, presenting on Tuesday, September 15 at 4:30 PM (EDT). A live webcast of the presentation will be available to the public at https://wsw.com/webcast/hcw7/dcth/1592203
• Oppenheimer Fall Healthcare Life Science & Med Tech Summit, participating on September 23, 2020.

Management will be available for virtual one-on-one meetings during both conferences. To schedule a meeting with management, please contact your conference representative or James@HaydenIR.com. 

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the Phase 3 FOCUS Trial, we have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called The ALIGN Trial. We currently are also evaluating other forms of metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com

Brett Maas
(646) 536-7331
brett@haydenir.com

FAQ

What is the schedule for Delcath Systems' upcoming investor conferences?

Delcath Systems will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:30 PM EDT, and participate in the Oppenheimer Fall Healthcare Life Science & Med Tech Summit on September 23, 2020.

How can I watch the Delcath Systems presentation at the H.C. Wainwright conference?

The presentation can be accessed via a live webcast available to the public at: https://wsw.com/webcast/hcw7/dcth/1592203.

What is the Melphalan Hydrochloride product by Delcath Systems?

Melphalan Hydrochloride for Injection is an investigational product designed to deliver high-dose chemotherapy specifically to the liver for treating liver cancers.

Has Melphalan Hydrochloride received FDA approval?

No, Melphalan Hydrochloride has not been approved by the U.S. Food & Drug Administration for sale in the U.S.

What is the Delcath CHEMOSAT® Hepatic Delivery System?

The Delcath CHEMOSAT® Hepatic Delivery System is marketed in Europe and is used to treat various liver cancers, having received CE Mark approval.